EP3756650
Samsetningar af (+)-2-[1-(3-etoxý-4-metoxý-fenýl)-2-metansúlfónýl-etýl]-4-asetýl-amínóísóindólín-1,3-díón
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
26.12.2012EP published:
20.8.2025EP application number:
20172615.5
EP translation filed:
3.11.2025Grant published:
15.12.2025EPO information:
European Patent Register
Max expiry date:
25.12.2032Expiry date:
25.12.2026Next due date:
31.12.2026
Title in English:
FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL]-4-ACETYL AMINOISOINDOLINE-1,3-DIONELanguage of the patent:
English
Timeline
Today
26.12.2012EP application
20.8.2025EP Publication
3.11.2025Translation submitted
15.12.2025Registration published
25.12.2026Expires
Owner
Name:
Amgen (Europe) GmbHAddress:
Floor 6-8 Suurstoffi 22, 6343 Risch-Rotkreuz, CH
Inventor
Name:
BHAT, Sreenivas S.Address:
Kendall Park, NJ 08824, US
Name:
KELLY, Michael T.Address:
Lake Hopatcong, NJ 07849, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201161580626 PDate:
27.12.2011Country:
US
Classification
Categories:
A61K 9/00, A61K 9/28, A61K 31/4035, A61P 29/00
Annual fees
Number
Paid
Expires
Payer
Number: 14
Paid: 19.12.2025
Expires: 25.12.2026
Payer: Árnason Faktor ehf.